Center for Neuroendocrine Tumors
The UCSF Center for Neuroendocrine Tumors provides comprehensive care for patients with all types of neuroendocrine tumors (NETs). Arising from cells that have traits of both nerve cells and endocrine cells, these rare tumors may produce hormones and can develop in many parts of the body, including the head and neck, lungs, pancreas and digestive tract.
We're equipped to handle any NET, no matter where it appears in the body or how it behaves. Our team includes surgeons, medical oncologists, radiation oncologists, radiologists, cardiologists, endocrinologists, symptom management experts, genetic counselors, nutritionists, psychologists, social workers and other specialists. We work together to provide patients with a precise diagnosis and treatment plan tailored to their particular case and needs.
All of our patients can expect to receive the latest and most effective therapies available for their condition. For a patient with a pancreatic NET, for example, the best treatment might involve minimally invasive surgery to remove the tumor. A patient with a gastrointestinal tumor might benefit from peptide receptor radionuclide therapy (PRRT), a new radiation technique that targets cancer cells. And we might use advanced screening tools, such as the UCSF500 Cancer Gene Panel test, to identify the precise biology behind another patient's tumor.
Our goal is to deliver world-class care from a holistic perspective. We make sure that our patients and their families have the support they need to face the physical, emotional and financial challenges that can arise after a cancer diagnosis. UCSF offers a wide range of cancer support services, including a bimonthly education and support group for patients with NETs and their loved ones.
Our locations
Our team
-
Emily Bergsland
MD
Gastrointestinal oncologist -
Rahul Aggarwal
MD
Genitourinary oncologist -
Mekhail Anwar
MD
Radiation oncologist -
Pelin Cinar
MD
Gastrointestinal oncologist -
Carlos Corvera
MD, FACS
Gastrointestinal cancer surgeon -
Mary Feng
MD
Radiation oncologist -
Nicholas Fidelman
MD
Interventional radiologist -
Matthew Gubens
MD, MS
Lung cancer specialist -
Thomas Hope
MD
Radiologist -
Hyunseok Kang
MD, MPH, FACP
Medical oncologist -
Wesley Kidder
MD, MPH
Gastrointestinal oncologist -
Umesh Masharani
MBBS
Endocrinologist -
Eric Nakakura
MD, PhD
Gastrointestinal cancer surgeon -
Sorbarikor Piawah
MD, MPH
Gastrointestinal oncologist -
Rajni K. Rao
MD
Cardiologist -
Angela Laffan
NP, MSN
Nurse practitioner -
Sheila Lindsay
NP, MSN
Nurse practitioner -
Rebecca Mirro
RN
Nurse navigator
Clinical trials
Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine...
The point estimate and 95% confidence interval of overall response rate will be obtained for each of the three liver-directed therapy groups (cryoablation, transarterial embolization(TAE) , radioembolization (RE)) separately. The ...
Recruiting
Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With C...
The primary endpoint for the study is the proportion of patients with undetectable serum PSA (< 0.2 ng/mL) at 6 months following completion of apalutamide therapy (18 months from date of randomization). Fisher's exact test will be...
Recruiting
Phase II Trial of AZD6738 Alone and in Combination With Olaparib
ORR will be measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and Will be based on one-sided exact binomial test comparison of the observed ORR in evaluable patients to the null-hypothesized valu...
Recruiting
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
ORR is defined as the proportion of the subjects in the analysis population who demonstrated complete response (CR) or partial response (PR) radiographically according to Response Evaluation Criteria in Solid Tumors (RECIST) versi...
Recruiting
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Comb...
DLT as graded using National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] Version 4.03. The DLT observation period may be increased if deemed appropriate by the Dose Escalation and Safety Committee
Recruiting
Awards & recognition
-
Best hospital in Northern California
-
Best in Northern California in cancer care
-
Designated comprehensive cancer center
Support services
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes
International Services
If you live in another country and are coming to UCSF for medical
treatment, our patient liaisons can help coordinate all aspects of your visit.
Interpreters
UCSF offers language services at no charge for patients with limited
English, as well as for patients who are deaf or have trouble hearing.
Hospital Stays
Checking into the hospital? Find helpful information by clicking on the relevant “Your Hospital Stay” booklet: Mission Bay, Parnassus or Mount
Zion.
Your Doctor Visit
See our top 10 tips for making your UCSF doctor’s appointment as stress-free and productive as possible.
Learn moreRelated clinics
Do you need pediatric care?
